Overview

Staccato® Granisetron Single Dose PK

Status:
Completed

Trial end date:
2020-01-19

Target enrollment:

Participant gender:

Summary

Part A: Single Ascending Dose in Healthy Volunteers This study will assess single ascending oral doses of AZ-010 in a placebo-controlled, double-blind design. The planned AZ-010 doses to be studied are 0.5 mg, 1 mg, and 3 mg. Part B: Single Dose Crossover in Healthy Volunteers 2-period, 2-treatment open-label crossover design study assessing the pharmacokinetic profiles of AZ-010 (1 mg) and granisetron for IV injection (1 mg).

Phase:

Phase 1

Details

Lead Sponsor:

Alexza Pharmaceuticals, Inc.

Collaborator:

Celerion

Treatments:

Granisetron